📣 VC round data is live. Check it out!
- Public Comps
- 10x Genomics
10x Genomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for 10x Genomics and similar public comparables like Insight Lifetech, BGI Genomics, GRAIL, Bloomage BioTechnology and more.
10x Genomics Overview
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Founded
2012
HQ

Employees
1.2K
Website
Financials (LTM)
EV
$2B
Valuation Multiples
Start free trial10x Genomics Financials
10x Genomics reported last 12-month revenue of $632M and negative EBITDA of ($49M).
In the same LTM period, 10x Genomics generated $435M in gross profit, ($49M) in EBITDA losses, and had net loss of ($66M).
Revenue (LTM)
10x Genomics P&L
In the most recent fiscal year, 10x Genomics reported revenue of $643M and EBITDA of $4M.
10x Genomics is unprofitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 1%, and net margin of (7%).
Financial data powered by Morningstar, Inc.
10x Genomics Stock Performance
10x Genomics has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
10x Genomics' stock price is $21.59.
10x Genomics share price decreased by 2.1% in the last 30 days, and increased by 126.6% in the last year.
10x Genomics has an EPS (earnings per share) of $-0.34.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 0.0% | -2.1% | -6.3% | 126.6% | $-0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial10x Genomics Valuation Multiples
10x Genomics trades at 3.7x EV/Revenue multiple, and (47.2x) EV/EBITDA.
EV / Revenue (LTM)
10x Genomics Financial Valuation Multiples
As of May 10, 2026, 10x Genomics has market cap of $3B and EV of $2B.
10x Genomics has a P/E ratio of (42.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 10x Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


10x Genomics Margins & Growth Rates
10x Genomics decreased revenue by 5% and EBITDA by 2448% in the last fiscal year.
In the most recent fiscal year, 10x Genomics reported gross margin of 69%, EBITDA margin of 1%, and net margin of (7%).
10x Genomics Margins
10x Genomics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
10x Genomics Operational KPIs
10x Genomics' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.5M for the same period.
10x Genomics' Rule of 40 is (20%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
10x Genomics' Rule of X is (26%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
10x Genomics Competitors
10x Genomics competitors include Insight Lifetech, BGI Genomics, GRAIL, Bloomage BioTechnology, Veracyte, Adaptive Biotech, Genus, Twist Bioscience, Syngene and Generate Biomedicines.
Most 10x Genomics public comparables operate across Life Sciences Tools, Diagnostics & Genomics, BioTech, DeepTech and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 32.7x | — | 147.3x | — | |||
| 4.1x | 4.1x | 52.0x | 48.2x | |||
| 12.7x | 11.8x | (5.0x) | (5.2x) | |||
| 4.6x | 4.5x | 26.7x | 25.9x | |||
| 5.5x | 5.2x | 19.8x | 19.3x | |||
| 7.5x | 7.4x | 164.9x | 258.5x | |||
| 2.6x | 2.6x | 14.7x | 13.3x | |||
| 9.2x | 8.3x | (73.8x) | (89.9x) | |||
This data is available for Pro users. Sign up to see all 10x Genomics competitors and their valuation data. Start Free Trial | ||||||
10x Genomics Funding History
Before going public, 10x Genomics raised $238M in total equity funding, across 5 rounds.
Last private valuation of 10x Genomics was $1B, after raising $35M in January 2019 from Fidelity, Meritech Capital Partners, and Wells Fargo.
10x Genomics Funding Rounds
10x Genomics M&A Activity
10x Genomics has acquired 7 companies to date.
Last acquisition by 10x Genomics was on August 7th 2025. 10x Genomics acquired Scale Biosciences for $30M (EV/Revenue multiple of ).
Latest Acquisitions by 10x Genomics
| Description | Scale Biosciences is a life sciences company developing single-cell profiling technologies for genomics, transcriptomics, and multi-omics research. The firm's scalable platforms enable high-throughput analysis of thousands of cells per sample, supporting drug discovery and precision medicine applications. Scale Biosciences serves academic labs, biopharma companies, and research institutes with automated workflows and cloud-based data processing. | Tetramer Shop is a supplier of MHC tetramers for detecting and monitoring antigen-specific T cells in immunotherapy research. Martinsried-headquartered near Munich, it offers fluorescently labeled tetramers for HLA-A2, HLA-B7, and other alleles used in flow cytometry assays. Products support T cell epitope mapping in vaccine development and cancer immunology studies. | ReadCoor is a Seattle-headquartered biotech firm offering the RC2 spatial multi-omics platform for tissue analysis. The technology uses Fluorescent in situ Sequencing to map RNA, DNA, proteins, and drugs at nanoscale 3D resolution across entire tissue sections. Targeted at pharma companies like Bristol Myers Squibb and researchers at Stanford, ReadCoor processes samples from tumors and organs, revealing subcellular interactions. Launched in 2022 from the Wyss Institute, its FISSEQ method scales to thousands of targets per experiment. | CARTANA is a Swedish biotechnology company specializing in In Situ Sequencing for mapping gene expression in brain tissue. Located in Stockholm, its ISS technology analyzes hundreds of genes per cell while preserving tissue morphology. The platform supports neuroscience research, biomarker discovery, and treatment validation in areas like Alzheimer's and Parkinson's. Founded in 2014, CARTANA was acquired by 10x Genomics in 2020, expanding its reach to global labs studying cellular interactions. | |
| HQ Country | |||||
| HQ City | San Diego, CA | Copenhagen | — | Stockholm | |
| Deal Date | 7 Aug 2025 | 25 Feb 2021 | 5 Oct 2020 | 21 Sep 2020 | |
| Valuation | $30M | undisclosed | $407M | $35M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all 10x Genomics acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 10x Genomics
| When was 10x Genomics founded? | 10x Genomics was founded in 2012. |
| Where is 10x Genomics headquartered? | 10x Genomics is headquartered in United States. |
| How many employees does 10x Genomics have? | As of today, 10x Genomics has over 1K employees. |
| Who is the CEO of 10x Genomics? | 10x Genomics' CEO is Serge Saxonov. |
| Is 10x Genomics publicly listed? | Yes, 10x Genomics is a public company listed on Nasdaq. |
| What is the stock symbol of 10x Genomics? | 10x Genomics trades under TXG ticker. |
| When did 10x Genomics go public? | 10x Genomics went public in 2019. |
| Who are competitors of 10x Genomics? | 10x Genomics main competitors include Insight Lifetech, BGI Genomics, GRAIL, Bloomage BioTechnology, Veracyte, Adaptive Biotech, Genus, Twist Bioscience, Syngene, Generate Biomedicines. |
| What is the current market cap of 10x Genomics? | 10x Genomics' current market cap is $3B. |
| What is the current revenue of 10x Genomics? | 10x Genomics' last 12 months revenue is $632M. |
| What is the current revenue growth of 10x Genomics? | 10x Genomics revenue growth (NTM/LTM) is (0%). |
| What is the current EV/Revenue multiple of 10x Genomics? | Current revenue multiple of 10x Genomics is 3.7x. |
| Is 10x Genomics profitable? | No, 10x Genomics is not profitable. |
| What is the current EBITDA of 10x Genomics? | 10x Genomics has negative EBITDA and is not profitable. |
| What is 10x Genomics' EBITDA margin? | 10x Genomics' last 12 months EBITDA margin is (8%). |
| What is the current EV/EBITDA multiple of 10x Genomics? | Current EBITDA multiple of 10x Genomics is (47.2x). |
| What is the current FCF of 10x Genomics? | 10x Genomics' last 12 months FCF is ($4M). |
| What is 10x Genomics' FCF margin? | 10x Genomics' last 12 months FCF margin is (1%). |
| What is the current EV/FCF multiple of 10x Genomics? | Current FCF multiple of 10x Genomics is (573.9x). |
| How many companies 10x Genomics has acquired to date? | As of May 2026, 10x Genomics has acquired 6 companies. |
| What was the largest acquisition by 10x Genomics? | $407M acquisition of ReadCoor on 5th October 2020 was the largest M&A 10x Genomics has done to date. |
| What companies 10x Genomics acquired? | 10x Genomics acquired ReadCoor, CARTANA, Scale Biosciences, EPINOMICS, Tetramer Shop, and Spatial Transcriptomics. |
| In how many companies 10x Genomics has invested to date? | 10x Genomics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to 10x Genomics
Lists including 10x Genomics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


